Is Ventyx Biosciences Stock a Good Investment?
Ventyx Biosciences Investment Advice | VTYX |
- Examine Ventyx Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ventyx Biosciences' leadership team and their track record. Good management can help Ventyx Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Ventyx Biosciences' business and its evolving consumer preferences.
- Compare Ventyx Biosciences' performance and market position to its competitors. Analyze how Ventyx Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Ventyx Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ventyx Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ventyx Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ventyx Biosciences is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Ventyx Biosciences Stock
Researching Ventyx Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 85.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.44. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Ventyx Biosciences recorded a loss per share of 2.35. The entity had not issued any dividends in recent years.
To determine if Ventyx Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ventyx Biosciences' research are outlined below:
| Ventyx Biosciences generated a negative expected return over the last 90 days | |
| Ventyx Biosciences may become a speculative penny stock | |
| Ventyx Biosciences has high historical volatility and very poor performance | |
| Ventyx Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (192.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ventyx Biosciences currently holds about 250.45 M in cash with (166.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ventyx Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 1651 shares by John Nuss of Ventyx Biosciences at 5.4034 subject to Rule 16b-3 |
Ventyx Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ventyx Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ventyx Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Ventyx Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ventyx Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-15 | 2022-06-30 | -0.45 | -0.39 | 0.06 | 13 | ||
2024-05-09 | 2024-03-31 | -0.69 | -0.62 | 0.07 | 10 | ||
2022-05-12 | 2022-03-31 | -0.52 | -0.45 | 0.07 | 13 | ||
2024-02-27 | 2023-12-31 | -0.9 | -0.79 | 0.11 | 12 | ||
2024-08-09 | 2024-06-30 | -0.5743 | -0.45 | 0.1243 | 21 | ||
2022-11-03 | 2022-09-30 | -0.44 | -0.59 | -0.15 | 34 | ||
2023-08-10 | 2023-06-30 | -0.71 | -0.91 | -0.2 | 28 | ||
2022-03-23 | 2021-12-31 | -1 | -0.36 | 0.64 | 64 |
Know Ventyx Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ventyx Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ventyx Biosciences backward and forwards among themselves. Ventyx Biosciences' institutional investor refers to the entity that pools money to purchase Ventyx Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Opaleye Management Inc | 2024-06-30 | 1.2 M | State Street Corp | 2024-06-30 | 1.2 M | Parkman Healthcare Partners Llc | 2024-06-30 | 1.2 M | Schonfeld Strategic Advisors Llc | 2024-06-30 | 1.2 M | Sphera Funds Management Ltd. | 2024-06-30 | 1 M | Jpmorgan Chase & Co | 2024-06-30 | 987.3 K | Sio Capital Management, Llc | 2024-06-30 | 778.9 K | Walleye Trading Advisors, Llc | 2024-06-30 | 510.8 K | Deerfield Management Co | 2024-06-30 | 5.8 M | Citadel Advisors Llc | 2024-06-30 | 5.8 M |
Ventyx Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 121.62 M.Market Cap |
|
Ventyx Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.73) | |
| Return On Capital Employed | (0.81) | (0.77) | |
| Return On Assets | (0.69) | (0.73) | |
| Return On Equity | (0.79) | (0.75) |
Determining Ventyx Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Ventyx Biosciences is a good buy. For example, gross profit margin measures Ventyx Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ventyx Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Ventyx Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ventyx Biosciences. Check Ventyx Biosciences' Beneish M Score to see the likelihood of Ventyx Biosciences' management manipulating its earnings.
Evaluate Ventyx Biosciences' management efficiency
Ventyx Biosciences has return on total asset (ROA) of (0.3339) % which means that it has lost $0.3339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5424) %, meaning that it created substantial loss on money invested by shareholders. Ventyx Biosciences' management efficiency ratios could be used to measure how well Ventyx Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2024. Return On Capital Employed is likely to rise to -0.77 in 2024. At this time, Ventyx Biosciences' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 18.2 M in 2024, whereas Total Assets are likely to drop slightly above 207.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.17 | 2.52 | |
| Tangible Book Value Per Share | 4.17 | 2.52 | |
| Enterprise Value Over EBITDA | (0.51) | (0.53) | |
| Price Book Value Ratio | 0.59 | 0.62 | |
| Enterprise Value Multiple | (0.51) | (0.53) | |
| Price Fair Value | 0.59 | 0.62 | |
| Enterprise Value | 1.5 B | 943.6 M |
The strategic vision of Ventyx Biosciences management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Beta 0.366 |
Basic technical analysis of Ventyx Stock
As of the 22nd of November, Ventyx Biosciences has the Variance of 16.53, risk adjusted performance of (0.01), and Coefficient Of Variation of (3,446). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Ventyx Biosciences, as well as the relationship between them.Ventyx Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ventyx Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ventyx Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ventyx Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ventyx Biosciences' Outstanding Corporate Bonds
Ventyx Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ventyx Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ventyx bonds can be classified according to their maturity, which is the date when Ventyx Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Understand Ventyx Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ventyx Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 3.0 | |||
| Coefficient Of Variation | (3,446) | |||
| Standard Deviation | 4.07 | |||
| Variance | 16.53 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 22.25 | |||
| Value At Risk | (5.86) | |||
| Potential Upside | 6.88 | |||
| Skewness | 0.9521 | |||
| Kurtosis | 1.83 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 3.0 | |||
| Coefficient Of Variation | (3,446) | |||
| Standard Deviation | 4.07 | |||
| Variance | 16.53 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 22.25 | |||
| Value At Risk | (5.86) | |||
| Potential Upside | 6.88 | |||
| Skewness | 0.9521 | |||
| Kurtosis | 1.83 |
Consider Ventyx Biosciences' intraday indicators
Ventyx Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ventyx Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ventyx Biosciences time-series forecasting models is one of many Ventyx Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ventyx Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Ventyx Stock media impact
Far too much social signal, news, headlines, and media speculation about Ventyx Biosciences that are available to investors today. That information is available publicly through Ventyx media outlets and privately through word of mouth or via Ventyx internal channels. However, regardless of the origin, that massive amount of Ventyx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ventyx Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ventyx Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ventyx Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ventyx Biosciences alpha.
Ventyx Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Ventyx Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ventyx Biosciences Corporate Management
| Matthew Moore | Chief Officer | Profile | |
| Sheila MD | Executive Chairperson | Profile | |
| John Nuss | Chief Officer | Profile | |
| Martin MD | Chief Officer | Profile | |
| Prof MD | Pres Officer | Profile | |
| MBA JD | Chief Officer | Profile |
Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.